Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:4118 |
| Name | colon neuroendocrine neoplasm |
| Definition | |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation benign neoplasm organ system benign neoplasm gastrointestinal system benign neoplasm intestinal benign neoplasm colonic benign neoplasm colon neuroendocrine neoplasm |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| BRAF V600E | Dabrafenib | colon neuroendocrine neoplasm | predicted - sensitive | detail... |
| BRAF V600E | Binimetinib | colon neuroendocrine neoplasm | no benefit | detail... |
| BRAF V600E | Cobimetinib + Vemurafenib | colon neuroendocrine neoplasm | predicted - sensitive | detail... |
| BRAF V600E | Dabrafenib + Trametinib | colon neuroendocrine neoplasm | predicted - sensitive | detail... |
| BRAF V600E | Cetuximab + Encorafenib | colon neuroendocrine neoplasm | predicted - sensitive | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04954820 | Phase II | Lutetium Lu 177 dotatate | Assessment of the Schema of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated Neuroendocrine Tumor (ReLUTH) | Recruiting | FRA | 0 |
| NCT06055439 | Phase Ib/II | CHM-2101 CAR-T cells | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | Recruiting | USA | 0 |
| NCT06878664 | Phase III | Lutetium Lu 177 dotatate + Octreotide acetate Lanreotide acetate + Lutetium Lu 177 dotatate | Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (RIALTO) | Recruiting | FRA | ESP | 0 |